Association For Applied Psychophysiology and Biofeedback - Clinical Effectiveness of Biofeedback

Clinical Effectiveness of Biofeedback

Moss, LeVaque, and Hammond (2004) observed that “Biofeedback and neurofeedback seem to offer the kind of evidence-based practice that the health care establishment is demanding."

The Association for Applied Psychophysiology and Biofeedback (AAPB) and the International Society for Neurofeedback and Research (ISNR) have collaborated in validating and rating treatment protocols to address questions about the clinical efficacy of biofeedback and neurofeedback applications, like ADHD and headache. In 2001, Donald Moss, then president of the Association for Applied Psychophysiology and Biofeedback, and Jay Gunkelman, president of the International Society for Neurofeedback and Research, appointed a task force to establish standards for the efficacy of biofeedback and neurofeedback.

The Task Force document was published in 2002, and a series of white papers followed, reviewing the efficacy of a series of disorders. The white papers established the efficacy of biofeedback for functional anorectal disorders, attention deficit disorder, facial pain and temporomandibular disorder, hypertension, urinary incontinence, Raynaud's phenomenon, substance abuse, and headache.

A broader review was published and later updated applying the same efficacy standards to the entire range of medical and psychological disorders. The 2008 edition reviewed the efficacy of biofeedback for over 40 clinical disorders, ranging from alcoholism/substance abuse to vulvar vestibulitis. The ratings for each disorder depend on the nature of research studies available on each disorder, ranging from anecdotal reports to double blind studies with a control group. Thus, a lower rating may reflect the lack of research rather than the ineffectiveness of biofeedback for the problem.